|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, March 18, 2015 ) Dallas, TX - Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector.
Visudyne (verteporfin) is a photosensitizer molecule that was co-developed by QLT PhotoTherapeutics and Novartis Pharma AG for use in a two-step procedure involving the use of a non-thermal laser light, known as PDT. It was initially approved by the FDA in April 2000 for the treatment of patients with predominantly classical subfoveal CNV due to AMD.
Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=312781 . (This is a premium report priced at US$3495 for a single user License.)
Scope:
• Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Visudyne including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Visudyne for the top seven countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Inquire for discount at http://www.rnrmarketresearch.com/contacts/discount?rname=312781 .
Reasons to Buy:
• Understand and capitalize by identifying products that are most likely to ensure a robust return.
• Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
• Make more informed business decisions from insightful and in-depth analysis of Visudyne performance.
• Obtain sales forecast for Visudyne from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).
Table of Contents:
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Related Reports 10
3 Disease Overview 12
3.1 Macular Degeneration Overview 12
3.1.1 Etiology and Pathophysiology 14
3.1.2 Classification 18
3.1.3 Symptoms and Diagnosis 20
3.2 Macular Edema Overview 23
3.2.1 Etiology and Pathophysiology 24
3.2.2 Classification 27
3.2.3 Symptoms and Diagnosis 28
4 Disease Management 31
4.1 Diagnosis and Treatment Overview 31
4.1.1 Macular Edema Diagnosis 31
4.1.2 Macular Degeneration Diagnosis 31
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 32
4.1.4 Clinical Practice 34
5 Competitive Assessment 48
5.1 Overview 48
6 Visudyne (verteporfin) 50
6.1 Overview 50
6.2 Efficacy - Macular Degeneration 52
6.3 Safety 53
6.4 SWOT Analysis 53
6.5 Forecast 54
7 Appendix 55
7.1 Bibliography 55
7.2 Abbreviations 67
7.3 Methodology 70
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
